Основная статистика
| CIK | 1711754 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to INmune Bio, Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2025 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of in |
|
| August 7, 2025 |
Exhibit 99.1 INmune Bio Inc. Announces Second Quarter 2025 Results, Provides Business Update and Announces Management Changes BOCA RATON, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) - INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results fo |
|
| August 7, 2025 |
Employment Agreement, dated December 16, 2021, between INmune Bio Inc. and Cory Ellspermann†* Exhibit 10.5 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) dated November 15, 2021 by and between INmune Bio, Inc., a corporation duly organized under the laws of the State of Nevada |
|
| August 7, 2025 |
Exhibit 99.2 INmune Bio’s CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment BOCA RATON, FL, Aug. 04, 2025 (GLOBE NEWSWIRE) - INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology and inflammation company, is pleased to report that its Phase I/II trial (the “CaRe PC” trial) of INKmune™ for men with metastat |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38793 INMUNE BIO INC. (Exact name of registrant as |
|
| August 7, 2025 |
Severance Agreement, dated August 4, 2025, between INmune Bio Inc. and Raymond J. Tesi†* Exhibit 10.4 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. This SEPARATION AGREEMENT AND MUTUAL RELEASE (“Agreement”) is made and entered into by and between Raymond Joseph Tesi, an individual and having a primary address at [***] (“Executive”), an |
|
| July 29, 2025 |
Exhibit 99.1 INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro™ Presented at the Alzheimer’s Association International Conference Boca Raton, July 29, 2025 (GLOBE NEWSWIRE) - INmune Bio Inc. (NASDAQ: INMB) announced today that a video detailing the additional findings from the Phase 2 MINDFuL trial evaluating XPro™, a novel selective soluble TNF inhibitor, will be published on t |
|
| July 29, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2025 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of inc |
|
| July 29, 2025 |
Exhibit 99.2 1 Corporate Presentation August 2025 NASDAQ: INMB 2 FORWARD LOOKING STATEMENTS This presentation contains “forward - looking statements” Forward - looking statements reflect our current view about future events. When used in this presentation, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as |
|
| July 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2025 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of inc |
|
| July 25, 2025 |
Exhibit 99.1 INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro™ at the Alzheimer’s Association International Conference Boca Raton, July 24, 2025 (GLOBE NEWSWIRE) - INmune Bio Inc. (NASDAQ: INMB) announced today that additional analyses from its Phase 2 MINDFuL trial evaluating XPro™, a novel selective soluble TNF inhibitor, will be released in an oral presentation at the Alzheimer’s As |
|
| June 30, 2025 |
Exhibit 99.2 INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Boca Raton, Florida, June 30, 2025 (GLOBE NEWSWIRE) - INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, today announced that it has closed its registered direct offering, announced on June 27, 2025, (the |
|
| June 30, 2025 |
Exhibit 99.1 INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Boca Raton, Florida, June 27, 2025 (GLOBE NEWSWIRE) - INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, today announced that it has entered into securities purchase agreements with two healthcare focused institution |
|
| June 30, 2025 |
Form of Securities Purchase Agreement, dated June 27, 2025 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 27, 2025, between INmune Bio Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set forth |
|
| June 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2025 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of inc |
|
| June 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2025 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of inc |
|
| June 30, 2025 |
Exhibit 99.1 INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer’s Disease In the Phase 2 MINDFuL trial of XPro™ in patients with early Alzheimer’s Disease (AD) with biomarkers of inflammation, the modified intent-to-treat (mITT) population (n=200) did not meet the primary cognitive endpoint (EMACC), however in a predefined population of amyloid-positive early AD |
|
| June 30, 2025 |
Exhibit 99.2 1 Corporate Presentation June 2025 NASDAQ: INMB 2 FORWARD LOOKING STATEMENTS This presentation contains “forward - looking statements” Forward - looking statements reflect our current view about future events. When used in this presentation, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as t |
|
| June 30, 2025 |
3,000,000 Shares of Common Stock PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (To the Prospectus Dated May 1, 2024) Registration No. |
|
| June 30, 2025 |
Form of Placement Agency Agreement, dated June 27, 2025 Exhibit 10.2 A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor New York, NY 10022 June 27, 2025 INmune Bio Inc. 225 NE Mizner Blvd., Suite 640 Boca Raton, Florida 33432 Attention: David J. Moss, Chief Financial Officer Re: Placement Agency Agreement Dear Mr. Moss: Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners (th |
|
| June 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2025 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of inc |
|
| June 26, 2025 |
Exhibit 99.1 INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer’s on Monday, June 30th Company to host a conference call to discuss results at 8:00am EDT on June 30, 2025 Boca Raton, Florida, June 26, 2025 (GLOBE NEWSWIRE) - INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, will host a conference call on Mo |
|
| June 16, 2025 |
EX-FILING FEES 4 ea024481801ex-feeimmunebio.htm FILING FEE TABLE Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) INmune Bio Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate |
|
| June 16, 2025 |
As filed with the Securities and Exchange Commission on June 13, 2025 As filed with the Securities and Exchange Commission on June 13, 2025 Registration No. |
|
| June 16, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) INmune Bio Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0001 |
|
| June 16, 2025 |
As filed with the Securities and Exchange Commission on June 13, 2025 As filed with the Securities and Exchange Commission on June 13, 2025 Registration No. |
|
| June 10, 2025 |
Exhibit 10.1 SECOND AMENDED AND RESTATED INMUNE BIO INC. 2021 STOCK INCENTIVE PLAN 1 General 1.1 Purpose. The purposes of the Second Amended and Restated INmune Bio Inc. 2021 Stock Incentive Plan (the “Plan”) is to promote the interests of INmune Bio Inc. (the “Company”) and the stockholders of the Company by providing (i) executive officers and other employees of the Company and its Subsidiaries |
|
| June 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2025 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of inc |
|
| June 10, 2025 |
Exhibit 99.1 XPro™ Reduces Amyloid and Enhances Behavior Post Traumatic Brain Injury in an Animal Model of Alzheimer’s Disease: Supported by Department of Defense XPro™ Treatment Post-TBI Prevents Short- and Long-Term Alzheimer’s-like Pathology in transgenic mice Boca Raton, Florida, June 10, 2025 (GLOBE NEWSWIRE) - INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of inco |
|
| May 14, 2025 |
INmune Bio Inc. Announces Attendance at the 2025 RBC Capital Markets Global Healthcare Conference Exhibit 99.1 INmune Bio Inc. Announces Attendance at the 2025 RBC Capital Markets Global Healthcare Conference BOCA RATON, Fla., May 14, 2025 (GLOBE NEWSWIRE) - INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system, today announces that the Company will be presenting at the 2025 RBC Capital Mark |
|
| May 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Amendment No. 1) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934, as Amended Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6( |
|
| May 8, 2025 |
Exhibit 99.1 INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update Conference Call Today at 4:30pm ET BOCA RATON, Fla., May 08, 2025 (GLOBE NEWSWIRE) - INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system, today announces its financial results for the quarter ended M |
|
| May 8, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of incor |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38793 INMUNE BIO INC. (Exact name of registrant a |
|
| May 7, 2025 |
Letter from Marcum LLP dated May 7, 2025 Exhibit 16.1 May 7, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by INmune Bio Inc. under Item 4.01 of its Form 8-K dated May 7, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of INmune Bio Inc. contained therein. Very trul |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of incor |
|
| May 5, 2025 |
Exhibit 99.1 INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th Boca Raton, Florida, May 05, 2025 (GLOBE NEWSWIRE) - INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer’s Disease (AD), today announced that it wi |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| April 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 –––––––––––––––––––––––––––––––––– SCHEDULE 14A Information –––––––––––––––––––––––––––––––––– Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use |
|
| April 16, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2025 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of in |
|
| April 16, 2025 |
INmune Bio Receives Favorable Patentability Opinion for CORDStrom™ Platform Technology Exhibit 99.1 INmune Bio Receives Favorable Patentability Opinion for CORDStrom™ Platform Technology Boca Raton, Florida, US, April 15, 2025 (GLOBE NEWSWIRE) - INmune Bio Inc. (NASDAQ: INMB), a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system, today announced a major intellectual property milestone with respect to its next-generation mesenc |
|
| April 14, 2025 |
Exhibit 99.1 INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness Stevenage, UK, and Boca Raton, Florida, US, April 14, 2025 (GLOBE NEWSWIRE) - INmune Bio Inc. (NASDAQ: INMB) a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system has partnered with the Cell and Gene Therapy Catap |
|
| April 14, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2025 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of in |
|
| April 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2025 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of inc |
|
| April 9, 2025 |
Exhibit 99.1 ALZHEIMER’S DISEASE (AD) AND INFLAMMATION: BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS FROM A PHASE - 2 STUDY OF XPRO1595 IN EARLY AD Parris Pope 1 , Therese Blomberg 1 , Kim A Staats 1 , Sarah Barnum 2 , Judith Jaeger 2 , R.J. Tesi 1 , C.J. Barnum 1 1 INmune Bio, Inc., Boca Raton, FL (USA), 2 Cognition Metrics LLC, Stamford, CT (US) Background and Aim » Dysregulated activation |
|
| April 1, 2025 |
MINDFuL Phase II Blinded, Randomized, Placebo-Controlled Data Anticipated June 2025 Exhibit 99.1 INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study MINDFuL Phase II Blinded, Randomized, Placebo-Controlled Data Anticipated June 2025 Boca Raton, Florida, April 01, 2025 (GLOBE NEWSWIRE) - INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments |
|
| April 1, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2025 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of inc |
|
| March 27, 2025 |
Exhibit 19.1 INmune Bio, Inc. Policy on Insider Trading This Insider Trading Policy describes the standards of INmune Bio Inc. and its subsidiaries (the “Company”) on trading, and causing the trading of, the Company’s securities or securities of certain other publicly traded companies while in possession of confidential information. This Policy is divided into two parts: the first part prohibits t |
|
| March 27, 2025 |
Exhibit 99.1 INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update Company to Host Conference Call Today, March 27, at 4:30pm ET BOCA RATON, Fla., March 27, 2025 (GLOBE NEWSWIRE) - INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient’s innate immune system to fight dis |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38793 INMUNE BIO INC. (Exact name of registra |
|
| March 27, 2025 |
Exhibit 21.1 Subsidiaries Jurisdiction of Formation INmune Bio International Ltd. England INmune Bio Australia Pty Ltd Australia DN02, Inc. United States |
|
| March 27, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2025 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of in |
|
| March 24, 2025 |
Exhibit 99.1 INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025 Boca Raton, Florida, March 24, 2025 (GLOBE NEWSWIRE) - INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, today announced that it will host a conference call on Thursday, March 27, 2025, at 4:30pm EDT to discuss results for i |
|
| March 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2025 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of in |
|
| March 7, 2025 |
Up to 3,898,852 Shares of Common Stock Underlying Previously Issued Warrants Filed Pursuant to Rule 424(b)(5) Registration No. 333-279036 PROSPECTUS SUPPLEMENT (To Prospectus dated August 7, 2024) Up to 3,898,852 Shares of Common Stock Underlying Previously Issued Warrants This prospectus relates to the issuance by INmune Bio Inc. of up to 3,898,852 shares of our common stock issuable from time to time upon exercise of certain warrants that we previously issued in our (i) |
|
| March 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2025 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of inc |
|
| March 4, 2025 |
Exhibit 99.1 INMB Nasdaq In vivo activation of mlNK cells with INKmune Preliminary results from a phase I/II trial in metastatic, castration - resistant prostate cancer Mark Lowdell CSO INmuneBio Inc INMB Nasdaq Innate Killer Summit March 2025 2 FORWARD LOOKING STATEMENTS This presentation contains “forward - looking statements” Forward - looking statements reflect our current view about future ev |
|
| February 12, 2025 |
INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer Exhibit 99.1 INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer ● Medical review of Phase 1 cohorts demonstrated no safety issues ● Data to be presented at the 10th Annual Innate Killer Summit, March 3-5 BOCA RATON, Fla, Feb. 12, 2025 (GLOBE NEWSWIRE) - INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology and inflammation company, continues to |
|
| February 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2025 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of |
|
| February 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2025 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of |
|
| February 10, 2025 |
Exhibit 10.1 LICENSE AGREEMENT This License Agreement (this “Agreement”) is entered into as of the date of last signature below (the “Effective Date”), by and between INmune Bio Inc., a corporation formed under laws of the state of Nevada in the United States of America, having a place of business at 225 NE Mizner Blvd., Suite 640, Boca Raton, Florida 33432 (“Licensee”) and Great Ormond Street Hos |
|
| February 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2025 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of |
|
| February 10, 2025 |
Exhibit 99.1 Corporate Presentation Inflammation & Immunology Platforms XPro / CORDStrom / INKmune ® INMB Nasdaq February 2025 v19 FORWARD LOOKING STATEMENTS This presentation contains “forward - looking statements” Forward - looking statements reflect our current view about future events. When used in this presentation, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” |
|
| February 10, 2025 |
Exhibit 99.1 INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) ● The Company reports results of a double-blinded, randomized, placebo-controlled study, known as “MissionEB,” investigating CORDStrom for treatment of RDEB in pediatric patients, which evidence a favorable benefit |
|
| February 10, 2025 |
Exhibit 99.2 1 RDEB – An Ultra - Rare Genetic Disease with Significant Unmet Need *Recessive Dystrophic Epidermolysis Bullosa (RDEB) • RDEB is a severe form of epidermolysis bullosa (EB), a rare disease that causes severe skin fragility, itch and chronic pain • Children with RDEB have skin that is damaged by even the smallest amount of friction which causes severe blistering, deep wounds, and scar |
|
| February 10, 2025 |
Exhibit 10.2 February 6, 2025 INmune Bio, Inc. 225 NE Mizner Blvd., Ste. 640 Boca Raton, FL 33432 Attn: Re: Termination Letter Dear David Moss: We refer to the Loan and Security Agreement dated as of June 10, 2021 (as the same may from time to time have been amended, restated, or otherwise modified, the “Loan Agreement”) by and between INmune Bio, Inc. (“Borrower”) and SILICON VALLEY BANK, a divis |
|
| January 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2025 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of |
|
| January 28, 2025 |
Exhibit 99.1 INmune Bio Inc. Expands INKmune Trial in Prostate Cancer to Veterans First patient treated in Phase II portion of clinical trial in metastatic prostate cancer at the West Los Angeles Veterans Administration Hospital Boca Raton, Florida, Jan. 28, 2025 (GLOBE NEWSWIRE) - INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on deve |
|
| January 15, 2025 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated January 15, 2025 with respect to the common stock, par value $0.001 per share, of INmune Bio Inc., and any amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) un |
|
| December 9, 2024 |
Exhibit 4.5 INMUNE BIO INC. AMENDMENT NO. 4 TO RIGHTS AGREEMENT This Amendment No. 4 (this “Amendment”), dated as of December 6, 2024, to the Rights Agreement, dated December 30, 2020, as amended on December 20, 2021, December 9, 2022 and December 14, 2023 (the “Rights Agreement”), between INmune Bio Inc., a Nevada corporation (the “Company”), and VStock Transfer LLC, as rights agent (the “Rights |
|
| December 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2024 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| December 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A/A (Amendment No. 4) FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 INMUNE BIO INC. (Exact name of registrant as specified in its charter) Nevada 47-5205835 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identifi |
|
| December 9, 2024 |
INMUNE BIO INC. AMENDMENT NO. 4 TO RIGHTS AGREEMENT Exhibit 4.1 INMUNE BIO INC. AMENDMENT NO. 4 TO RIGHTS AGREEMENT This Amendment No. 4 (this “Amendment”), dated as of December 6, 2024, to the Rights Agreement, dated December 30, 2020, as amended on December 20, 2021, December 9, 2022 and December 14, 2023 (the “Rights Agreement”), between INmune Bio Inc., a Nevada corporation (the “Company”), and VStock Transfer LLC, as rights agent (the “Rights |
|
| November 14, 2024 |
Exhibit 99.1 INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease Boca Raton, Florida, Nov. 13, 2024 (GLOBE NEWSWIRE) - INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease announced today that it comp |
|
| November 14, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of |
|
| November 13, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of |
|
| November 13, 2024 |
Exhibit 99.1 Inflammation and Immunology Repair Two Platforms in the Clinic: XPro and INKmune INMB Nasdaq November 2024 v4b 2 FORWARD LOOKING STATEMENTS This presentation contains “forward - looking statements” Forward - looking statements reflect our current view about future events. When used in this presentation, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan |
|
| November 1, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2024 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of |
|
| November 1, 2024 |
Exhibit 99.1 INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update BOCA RATON, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) - INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the quarter |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38793 INMUNE BIO INC. (Exact name of registra |
|
| October 28, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2024 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of |
|
| October 28, 2024 |
Exhibit 99.1 INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB “Why EMACC is the Optimal Tool for Measuring Cognitive Change in Early Alzheimer’s Trials” Webinar to be Held on November 7, 2024, at 1 PM ET. Poster on EMACC Sensitivity and Performance in Phase II Alzheimer’s Trial to be Presented at CTAD2024 Boca Raton, Florida, Oct. 28, 2024 (GLOBE NEWSWIRE) - INmune Bio, |
|
| October 25, 2024 |
INMB / INmune Bio, Inc. / HIGHBRIDGE CAPITAL MANAGEMENT LLC Passive Investment SC 13G 1 p24-3020sc13g.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Inmune Bio Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 45782T105 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designat |
|
| October 25, 2024 |
Exhibit 99.1 INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination Data from Animal Model Study Demonstrate XPro™ converts microglia from a demyelinating cell to a remyelinating cell Multi-year study published has implications for many CNS diseases including Alzheimer’s Boca Raton, Florida, Oct. 24, 2024 (GLOBE NEWSWIRE) - INmune Bio, Inc. (NASDAQ: INMB) |
|
| October 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2024 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of |
|
| October 24, 2024 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2024 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of |
|
| October 24, 2024 |
Exhibit 99.1 INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024 Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, Oct. 24, 2024 (GLOBE NEWSWIRE) - INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company targeting microglial activation and neuroinflam |
|
| October 11, 2024 |
INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit Exhibit 99.1 INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit Boca Raton, Florida, Oct. 11, 2024 (GLOBE NEWSWIRE) - INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer’s Disease (AD), today announced that management will participate in the upcoming Max |
|
| October 11, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2024 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of |
|
| October 2, 2024 |
INMB / INmune Bio, Inc. / Xencor Inc - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| September 26, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2024 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer o |
|
| September 26, 2024 |
INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort Exhibit 99.1 INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort BOCA RATON, Fla., Sept. 26, 2024 (GLOBE NEWSWIRE) - INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology and inflammation company, continues to advance its Natural Killer (NK) cell therapy, INKmune™, in a Phase I/II trial (the “CaRe PC” trial) for men with metastatic Cas |
|
| September 17, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2024 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer o |
|
| September 17, 2024 |
Exhibit 99.1 INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer’s Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints BOCA RATON, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) - INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology and inflammation company, today announced that results of additional analysis of blinded data |
|
| September 16, 2024 |
Form of Placement Agency Agreement Exhibit 10.2 A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor New York, NY 10022 September 12, 2024 INmune Bio Inc. 225 NE Mizner Blvd., Suite 640 Boca Raton, Florida 33432 Attention: David J. Moss, Chief Financial Officer Re: Placement Agency Agreement Dear Mr. Moss: Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partner |
|
| September 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2024 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer o |
|
| September 16, 2024 |
Exhibit 4.1 COMMON STOCK PURCHASE WARRANT INMUNE BIO Inc. Warrant Shares: Issue Date: September 16, 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after March 16, 2025 (the “Initial Exercise Dat |
|
| September 16, 2024 |
2,341,260 Shares of Common Stock Warrants to Purchase up to 2,341,260 Shares of Common Stock PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (To the Prospectus Dated May 1, 2024) Registration No. |
|
| September 16, 2024 |
INmune Bio Announces $13.0 Million Registered Direct Offering Exhibit 99.1 INmune Bio Announces $13.0 Million Registered Direct Offering Boca Raton, Florida, Sept. 12, 2024 (GLOBE NEWSWIRE) - INmune Bio Inc. (Nasdaq: INMB) (the “Company” or “INmune Bio”), a clinical- stage inflammation and immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced it has entered into securities purchase |
|
| September 16, 2024 |
Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 12, 2024, between INmune Bio Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set f |
|
| September 3, 2024 |
INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference Exhibit 99.1 INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference Boca Raton, Florida, Sept. 03, 2024 (GLOBE NEWSWIRE) - INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced that management will participate in the foll |
|
| September 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2024 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of |
|
| August 9, 2024 |
Exhibit 1.1 INMUNE BIO INC. UP TO $75,000,000 OF COMMON STOCK (par value $0.001 per share) AMENDED & RESTATED At-the-market SALES AGREEMENT August 9, 2024 RBC Capital Markets, LLC 200 Vesey Street, 8th Floor New York, NY 10281 BTIG, LLC 65 East 55th Street New York, NY 10022 Ladies and Gentlemen: INmune Bio Inc., a Nevada corporation ( the “Company”), confirms its agreement (this “Agreement”) with |
|
| August 9, 2024 |
Up to $75,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-279036 PROSPECTUS SUPPLEMENT (To the Prospectus Dated August 7, 2024) Up to $75,000,000 Common Stock We have entered into an amended and restated at-the-market sales agreement, or the Sales Agreement, with RBC Capital Markets, LLC and BTIG, LLC, or the Sales Agents, each acting in its respective capacity as a sales agent, relating to the offer |
|
| August 9, 2024 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2024 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of in |
|
| August 5, 2024 |
INmune Bio Inc. 225 NE Mizner Blvd., Suite 640 Boca Raton, Florida 33432 INmune Bio Inc. 225 NE Mizner Blvd., Suite 640 Boca Raton, Florida 33432 (858)-964-3720 August 5, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: INmune Bio Inc. Registration Statement on Form S-3 File No. 333-279036 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, |
|
| August 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of in |
|
| August 2, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) INmune Bio Inc. (Exact name of Registrant as Specified in its Charter) Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forwar |
|
| August 2, 2024 |
As filed with the Securities and Exchange Commission on August 2, 2024. As filed with the Securities and Exchange Commission on August 2, 2024. Registration No. 333-279036 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INMUNE BIO INC. (Exact name of registrant as specified in its charter) Nevada 47-5205835 (State or Other Jurisdiction of Incorporation or Organi |
|
| August 2, 2024 |
Exhibit 99.1 INmune Bio Inc. Announces Second Quarter 2024 Results and Provides Business Update Company to Host Conference Call Today, August 1, at 4:30pm ET BOCA RATON, Fla., Aug. 01, 2024 (GLOBE NEWSWIRE) - INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company developing treatments that harness the patient’s innate immune system to fight disease, to |
|
| August 1, 2024 |
First Amendment to the Bylaws of INmune Bio Inc. Exhibit 3.1 FIRST AMENDMENT TO BYLAWS OF INMUNE BIO, INC. WHEREAS, the Board of Directors (the “Board”) of INmune Bio, Inc., a Nevada Corporation (the “Company”), has deemed it advisable and in the best interest of the Company and its stockholders, pursuant to the Board’s Authority set forth in Article IX, Section 1,of the Bylaws of the Company (the “Bylaws”), to adopt amendments to the Bylaws to |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38793 INMUNE BIO INC. (Exact name of registrant as |
|
| August 1, 2024 |
INmune Bio Inc. 225 NE Mizner Blvd., Suite 640 Boca Raton, Florida 33432 August 1, 2024 INmune Bio Inc. 225 NE Mizner Blvd., Suite 640 Boca Raton, Florida 33432 (858)-964-372 August 1, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: INmune Bio Inc. Registration Statement on Form S-3 File No. 333-279036 Ladies and Gentlemen: Reference is made to our letter, filed as correspondence via EDGAR |
|
| July 30, 2024 |
Exhibit 99.1 INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024 Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 25, 2024 (GLOBE NEWSWIRE) - INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a patie |
|
| July 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2024 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of inc |
|
| July 30, 2024 |
INmune Bio Inc. 225 NE Mizner Blvd., Suite 640 Boca Raton, Florida 33432 INmune Bio Inc. 225 NE Mizner Blvd., Suite 640 Boca Raton, Florida 33432 (858)-964-3720 July 30, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: INmune Bio Inc. Registration Statement on Form S-3 File No. 333-279036 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, |
|
| July 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2024 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of inc |
|
| July 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2024 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of inco |
|
| July 1, 2024 |
Exhibit 99.1 INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer’s Disease Trial The planned interim analysis confirms the accuracy of the sample size calculations and statistical power for EMACC, the primary endpoint. The interim analysis, performed by a third-party, demonstrated no need to change trial design or size. BOCA RATON, Fla., June 27, 2024 (GLOBE NEWSWIRE) - INmun |
|
| July 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2024 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of inc |
|
| June 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2024 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of inc |
|
| June 13, 2024 |
Incentive Stock Option Agreement between INmune Bio Inc. and Dr. Tesi, dated June 10, 2024 Exhibit 10.1 Incentive Stock Option Agreement This Incentive Stock Option Agreement (this “Agreement”) is made and entered into as of June 10, 2024 by and between INmune Bio Inc., a Nevada corporation (the “Company”) and Raymond J. Tesi (the “Participant”). Grant Date: June 10, 2024 Exercise Price per Share: $8.72 Number of Option Shares: 37,882 Expiration Date: June 9, 2034 1. Grant of Option. 1. |
|
| May 30, 2024 |
INmune Bio Inc. to Join Russell 3000® Index Exhibit 99.1 INmune Bio Inc. to Join Russell 3000® Index Boca Raton, Florida, May 30, 2024 (GLOBE NEWSWIRE) - INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1st, |
|
| May 30, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2024 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of inco |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive |
|
| May 23, 2024 |
Exhibit 3.1 First Amendment to Bylaws Of Inmune Bio, Inc. WHEREAS, the Board of Directors (the “Board”) of INmune Bio, Inc., a Nevada Corporation (the “Company”), has deemed it advisable and in the best interest of the Company and its stockholders, pursuant to the Board’s Authority set forth in Article IX, Section 1,of the Bylaws of the Company (the “Bylaws”), to adopt amendments to the Bylaws to |
|
| May 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2024 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of inco |
|
| May 16, 2024 |
Form of Incentive Stock Option Agreement of INmune Bio Inc. Exhibit 10.2 Incentive Stock Option Agreement This Incentive Stock Option Agreement (this “Agreement”) is made and entered into as of May 14, 2024 by and between INmune Bio Inc., a Nevada corporation (the “Company”) and (the “Participant”). Grant Date: May 14, 2024 Exercise Price per Share: $9.92 Number of Option Shares: 160,000 Expiration Date: May 13, 2034 1. Grant of Option. 1.1 Grant; Type of |
|
| May 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of inco |
|
| May 16, 2024 |
Form of Nonqualified Option Agreement of INmune Bio Inc. Exhibit 10.1 INMUNE BIO, INC. 2021 STOCK INCENTIVE PLAN Form of Nonqualified Stock Option Agreement This NONQUALIFIED STOCK OPTION AGREEMENT (this “Agreement”), made and entered into on the 14th day of May 2024, by and between (the “Participant”) and INmune Bio, Inc., a Nevada corporation (the “Company”), sets forth the terms and conditions of stock options issued to the Participant by the Compens |
|
| May 13, 2024 |
Exhibit 99.1 INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9 Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, May 07, 2024 (GLOBE NEWSWIRE) - INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate |
|
| May 13, 2024 |
INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update Exhibit 99.2 INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update Company to Host Conference Call Today, May 9, at 4:30pm ET BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) - INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announc |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of incor |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38793 INMUNE BIO INC. (Exact name of registrant a |
|
| May 1, 2024 |
As filed with the Securities and Exchange Commission on May 1, 2024. As filed with the Securities and Exchange Commission on May 1, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INMUNE BIO INC. (Exact name of registrant as specified in its charter) Nevada 47-5205835 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Ide |
|
| May 1, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) INmune Bio Inc. (Exact name of Registrant as Specified in its Charter) Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forwar |
|
| April 30, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2024 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of in |
|
| April 30, 2024 |
Exhibit 99.1 INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Boca Raton, Florida, April 29, 2024 (GLOBE NEWSWIRE) - INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patien |
|
| April 30, 2024 |
Exhibit 99.2 INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years Boca Raton, Florida, April 30, 2024 (GLOBE NEWSWIRE) - INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system |
|
| April 26, 2024 |
Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 24, 2024, between INmune Bio Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set forth |
|
| April 26, 2024 |
986,000 Shares of Common Stock Warrants to Purchase up to 986,000 Shares of Common Stock PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (To the Prospectus Dated May 5, 2021) Registration No. |
|
| April 26, 2024 |
Exhibit 4.1 WARRANT TO PURCHASE SHARES OF COMMON STOCK INMUNE BIO INC. Warrant Shares: 986,000 Original Issuance Date: April 29, 2024 THIS WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, [*] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or |
|
| April 26, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2024 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of in |
|
| April 26, 2024 |
Exhibit 99.1 INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Boca Raton, Florida, April 25, 2024 (GLOBE NEWSWIRE) - INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced today that it has entered |
|
| April 26, 2024 |
Form of Placement Agency Agreement Exhibit 10.2 PLACEMENT AGENCY AGREEMENT April 24, 2024 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: This agreement (the “Agreement”) constitutes the agreement between Maxim Group LLC (“Maxim” or the “Placement Agent”) and INmune Bio Inc., a Nevada corporation (the “Company”), pursuant to which Maxim shall serve as the exclusive placement agent for the Compan |
|
| April 25, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2024 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of in |
|
| April 25, 2024 |
Exhibit 99.1 INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay Boca Raton, Florida, April 23, 2024 (GLOBE NEWSWIRE) - INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune sys |
|
| April 22, 2024 |
Exhibit 10.3 WARRANT TO PURCHASE SHARES OF COMMON STOCK INMUNE BIO INC. Warrant Shares: Original Issuance Date: April [ ], 2024 THIS WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the |
|
| April 22, 2024 |
Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [●], 2024, between INmune Bio Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set forth in t |
|
| April 22, 2024 |
571,592 Shares of Common Stock Warrants to Purchase up to 571,592 Shares of Common Stock PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (To the Prospectus Dated May 5, 2021) Registration No. |
|
| April 22, 2024 |
Exhibit 99.1 INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering Boca Raton, Florida, April 22, 2024 (GLOBE NEWSWIRE) - INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s |
|
| April 22, 2024 |
Form of Placement Agency Agreement Exhibit 10.2 PLACEMENT AGENCY AGREEMENT April 19, 2024 LifeSci Capital LLC 250 West 55th Street Suite 3401 New York, New York 10019 Ladies and Gentlemen: This agreement (the “Agreement”) constitutes the agreement between LifeSci Capital LLC (“LifeSci Capital” or the “Placement Agent”) and INmune Bio Inc., a Nevada corporation (the “Company”), pursuant to which LifeSci Capital shall serve as the ex |
|
| April 22, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2024 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of in |
|
| April 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38793 INMUNE BIO INC. (Ex |
|
| April 9, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2024 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of inc |
|
| April 9, 2024 |
Exhibit 99.1 INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024 Novel Immunotherapy Approach Targets Soluble Tumor Necrosis Factor to Overcome Resistance and Enhance Therapeutic Outcome in High-Risk Breast Cancer Boca Raton, Florida, April 08, 2024 (GLOBE NEWSWIRE) - INmune Bio, Inc. (NASDAQ: INMB) (the “Company |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of in |
|
| March 29, 2024 |
INMUNE BIO INC. CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share amounts) Exhibit 99.1 INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update Company to Host Conference Call Today, March 28, at 4:30pm ET BOCA RATON, Fla., March 28, 2024 (GLOBE NEWSWIRE) - INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today an |
|
| March 28, 2024 |
Exhibit 21.1 Subsidiaries Jurisdiction of Formation INmune Bio International Ltd. England INmune Bio Australia Pty Ltd Australia DN02, Inc. United States |
|
| March 28, 2024 |
INmune Bio Policy for recovery of erroneously awarded compensation* Exhibit 97.1 INmune Bio Inc. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION The Board of Directors (the “Board”) of INmune Bio Inc. (the “Company” or “INMB”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 2, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Se |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38793 INMUNE BIO INC. (Exact name of registra |
|
| March 27, 2024 |
Exhibit 99.1 INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28 Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, March 26, 2024 (GLOBE NEWSWIRE) - INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology and inflammation company focused on developing treatments that har |
|
| March 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2024 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of in |
|
| January 30, 2024 |
Exhibit 99.1 INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease Program The Phase II clinical trial in patients with Alzheimer’s disease with neuroinflammation is on track to complete enrollment mid-2024 with top line data expected approximately six months after the final patient is enrolled. BOCA RATON, Florida, Jan. 30, 2024 (GLOBE NEWSWIRE) - INmune Bio Inc. (NASDAQ: INMB |
|
| January 30, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2024 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of |
|
| January 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2024 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of i |
|
| January 2, 2024 |
Exhibit 99.1 INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer Boca Raton, Florida, Jan. 02, 2024 (GLOBE NEWSWIRE) - INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, dosed the |
|
| December 18, 2023 |
Exhibit 4.4 INMUNE BIO INC. AMENDMENT NO. 3 TO RIGHTS AGREEMENT This Amendment No. 3 (this “Amendment”), dated as of December 13, 2023, to the Rights Agreement, dated December 30, 2020, as amended on December 20, 2021 and December 9, 2022 (the “Rights Agreement”), between INmune Bio Inc., a Nevada corporation (the “Company”), and VStock Transfer LLC, as rights agent (the “Rights Agent”). WHEREAS, |
|
| December 18, 2023 |
Exhibit 99.1 INmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold Issued by the United States FDA Enrollment in the Company’s Phase II study using XProTM to treat patients with Alzheimer’s Disease with neuroinflammation is accelerating in sites outside the US and the Company is maintaining its timeline to successfully conclude the trial. In the US, the |
|
| December 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2023 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of |
|
| December 18, 2023 |
Exhibit 4.1 INMUNE BIO INC. AMENDMENT NO. 3 TO RIGHTS AGREEMENT This Amendment No. 3 (this “Amendment”), dated as of December 13, 2023, to the Rights Agreement, dated December 30, 2020, as amended on December 20, 2021 and December 9, 2022 (the “Rights Agreement”), between INmune Bio Inc., a Nevada corporation (the “Company”), and VStock Transfer LLC, as rights agent (the “Rights Agent”). WHEREAS, |
|
| December 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A/A (Amendment No. 3) FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 INMUNE BIO INC. (Exact name of registrant as specified in its charter) Nevada 47-5205835 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identifi |
|
| December 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2023 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction of incorporation) (Commission File Number |
|
| November 29, 2023 |
Exhibit 99.1 INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium INB03 increases uptake of deruxtecan, the immunotoxin associated with trastuzumab deruxtecan (T-DXd, ENHERTU®), in models of resistant MUC4 expressing HER2 positive breast cancer and increases the t |
|
| November 29, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2023 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of |
|
| November 27, 2023 |
Exhibit 99.1 INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s Disease Boca Raton, Florida, Nov. 27, 2023 (GLOBE NEWSWIRE) - INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company dedicated to advancing treatments that leverage the patient’s innate immune system to combat disease, announced today it |
|
| November 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2023 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of |
|
| November 15, 2023 |
INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer’s Disease in Europe Exhibit 99.1 INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer’s Disease in Europe The Company received regulatory approval to extend its Phase II trial of XPro™ in individuals with early Alzheimer’s disease in Poland, with additional European Union (EU) countries expected to open soon. The Company received a cash refund of approximately $2.8M USD pursuant to an Australi |
|
| November 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2023 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of |
|
| November 1, 2023 |
Exhibit 99.1 INmune Bio Inc. Announces Third Quarter 2023 Results and Provides Business Update Company to Host Conference Call Today, November 1, at 4:30pm ET BOCA RATON, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) - INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today a |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38793 INMUNE BIO INC. (Exact name of registra |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2023 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of |
|
| October 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2023 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of |
|
| October 31, 2023 |
Exhibit 99.1 INmune Bio Inc. Patent Claims Covering INB16 Cell Line and INKmune™ Therapeutic Composition given Favorable Patentability Opinion by International Search Authority INmune Bio receives International Search Report and Written Opinion communicating possession of novelty, inventive step, and industrial applicability in all claims pending in an international patent application covering, am |
|
| October 31, 2023 |
Exhibit 99.2 INmune Bio Inc. Presents Preclinical Data at SITC 2023 Showing INB03 is an Innate Immune Check Point Inhibitor that Downregulates SIRPα SIRP-CD47 is an innate immune checkpoint known as the “don’t eat me” signal. INB03 downregulates expression of SIRPα on macrophages promote increased cancer cell death by antibody dependent cellular phagocytosis (ADCP). Boca Raton, Florida, Oct. 30, 2 |
|
| October 18, 2023 |
Exhibit 99.2 INmune Bio Inc. Presents New Biomarker and Feasibility Data from Phase 1b Study Supporting the Use of XPro™ to Treat Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference An in-depth analysis of MRI gray matter microstructure following treatment with XPro™ shows that the greatest improvement was in the earliest and most affected regions of the AD brain; an ef |
|
| October 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2023 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of |
|
| October 18, 2023 |
Exhibit 99.1 INmune Bio Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, November 1 Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, Oct. 16, 2023 (GLOBE NEWSWIRE) - INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a patient’s |
|
| September 7, 2023 |
Exhibit 99.1 INmune Bio Inc. to Present at Baird Global Healthcare Conference and H.C Wainwright 25th Annual Global Investment Conference Boca Raton, FL, Sept. 07, 2023 (GLOBE NEWSWIRE) - INmune Bio (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness a patient’s immune system to fight disease, announced today that RJ Tesi, MD, Chief Executive Officer, |
|
| September 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2023 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of |
|
| September 5, 2023 |
Exhibit 99.1 INmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimer’s Disease The authorization provides approval for the Company to expand the ongoing Phase 2 trial of XPro™ in patients with early Alzheimer’s disease to the U.K. Boca Raton, Florida, Sept. 05, 2023 (GLOBE NEWSWIRE) - I |
|
| September 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2023 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of |
|
| August 16, 2023 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-254221 PROSPECTUS SUPPLEMENT (To the Prospectus Dated May 5, 2021) $28,701,161.61 Common Stock INMUNE BIO INC. This prospectus supplement and the accompanying base prospectus, which together we sometimes refer to as the prospectus, relate to the offer and sale, from time to time, of shares of our common stock having an aggregate gross sales pri |
|
| August 16, 2023 |
Exhibit 1.1 INMUNE BIO Inc. AMENDMENT NO. 1 TO At-the-market SALES AGREEMENT August 16, 2023 BTIG, LLC 65 East 55th Street New York, NY 10022 Ladies and Gentlemen: Reference is made to the At-The-Market Sales Agreement, dated March 10, 2021, including the Schedules and Exhibits thereto (the “Sales Agreement”), between INmune Bio Inc., a Nevada corporation (the “Company”), and BTIG, LLC (“BTIG” and |
|
| August 16, 2023 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2023 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of i |
|
| August 8, 2023 |
Exhibit 99.1 INmune Bio Inc. Announces Second Quarter 2023 Results and Provides Business Update Company to Host Conference Call Today, August 7, at 4:30pm ET BOCA RATON, Fla., Aug. 07, 2023 (GLOBE NEWSWIRE) - INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today an |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 INMUNE BIO INC. (Exact name of registrant as specified in its charter) Nevada |
|
| August 2, 2023 |
INmune Bio Inc. to Present at the BTIG Virtual Biotechnology Conference Exhibit 99.1 INmune Bio Inc. to Present at the BTIG Virtual Biotechnology Conference Boca Raton, FL, Aug. 01, 2023 (GLOBE NEWSWIRE) - INmune Bio (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness a patient’s immune system to fight disease, announced today that RJ Tesi, MD, CEO and David Moss, Chief Financial Officer, will present a corporate overview |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2023 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of in |
|
| August 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2023 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of inc |
|
| August 1, 2023 |
Exhibit 99.1 INmune Bio, Inc. to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on Monday, August 7 Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 31, 2023 (GLOBE NEWSWIRE) - INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a patient’s i |
|
| July 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2023 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of inc |
|
| July 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2023 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of inc |
|
| July 12, 2023 |
Exhibit 99.1 INmune Bio Inc. Announces Data Presented at the 16th European Meeting on Glial Cells in Health and Disease Shows that XPro™ Promotes Remyelination by Affecting Astroglial and Microglial Biology Neutralizing soluble TNF with XPro™ promotes remyelination in cuprizone model after increasing astrocyte and microglia activation responses Boca Raton, Florida, July 10, 2023 (GLOBE NEWSWIRE) - |
|
| July 12, 2023 |
Exhibit 99.2 INmune Bio Inc. Announces Novel MRI Biomarker Data Demonstrating Improvement in Gray Matter in Patients with Alzheimer’s Disease Analysis of MRI scans in participants from an open label Phase 1b study demonstrates that CDM®, a novel gray matter biomarker, is improved following three months of treatment with XPro1595TM Boca Raton, Florida, July 11, 2023 (GLOBE NEWSWIRE) - INmune Bio In |
|
| July 12, 2023 |
Exhibit 99.3 INmune Bio Inc. to Deliver Keynote Talk at 5th World Aging and Rejuvenation Conference. RJ Tesi MD, CEO of INmune Bio, to Present Opening Keynote on Drug Development Strategies to Improve Health Span by Treating the Chronic Diseases of Aging Boca Raton, Florida, July 12, 2023 (GLOBE NEWSWIRE) - INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focuse |
|
| June 20, 2023 |
As filed with the Securities and Exchange Commission on June 20, 2023 As filed with the Securities and Exchange Commission on June 20, 2023 Registration No. |
|
| June 20, 2023 |
As filed with the Securities and Exchange Commission on June 20, 2023 As filed with the Securities and Exchange Commission on June 20, 2023 Registration No. |
|
| June 20, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) INmune Bio Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock Other(2) 4,000,000 $ |
|
| June 1, 2023 |
Exhibit 10.1 AMENDED AND RESTATED INMUNE BIO, INC. 2021 STOCK INCENTIVE PLAN 1 General 1.1 Purpose. The purposes of the Amended and Restated INmune Bio, Inc. 2021 Stock Incentive Plan (the “Plan”) is to promote the interests of INmune Bio, Inc. (the “Company”) and the stockholders of the Company by providing (i) executive officers and other employees of the Company and its Subsidiaries (as defined |
|
| June 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of inco |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2023 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of inco |
|
| May 12, 2023 |
Exhibit 99.1 HARNESSING THE POWER OF THE INNATE IMMUNE SYSTEM INMB Webinar Phase I/II Trial of INKmune ʳ in Metastatic Castration - Resistant Prostate Cancer FORWARD LOOKING STATEMENTS This presentation contains “forward - looking statements . ” Forward - looking statements reflect our current view about future events . When used in this presentation, the words “anticipate,” “believe,” “estimate,” |
|
| May 8, 2023 |
Exhibit 99.1 INmune Bio, Inc. Announces FDA Clearance of IND Application for INKmune™, a Natural Killer Therapy, for a Phase I/II Trial in Metastatic Castration-Resistant Prostate Cancer ● Represents First Ever Natural Killer Immunotherapy trial in Metastatic Castration-Resistant Prostate Cancer ● Webinar at 11AM ET on Friday, May 12. BOCA RATON, Fla., May 08, 2023 (GLOBE NEWSWIRE) - INmune Bio, I |
|
| May 8, 2023 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of incor |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of incor |
|
| May 4, 2023 |
Exhibit 99.1 INmune Bio Inc. Announces First Quarter 2023 Results and Provides Business Update Company to Host Conference Call Today, May 3, at 4:30pm ET BOCA RATON, Fla., May 03, 2023 (GLOBE NEWSWIRE) - INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announc |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 INMUNE BIO INC. (Exact name of registrant as specified in its charter) Nevada |
|
| April 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2023 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of in |
|
| April 24, 2023 |
Exhibit 99.1 INmune Bio, Inc. to Report First Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, May 3 Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, April 24, 2023 (GLOBE NEWSWIRE) - INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a patient’s i |
|
| April 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive |
|
| April 20, 2023 |
Exhibit 99.1 XPro1595 Improves Outcomes in a Mouse Model of TBI-induced Alzheimer’s Disease TNF is involved in the development of Alzheimer’s Disease pathology following traumatic brain injury and is prevented by neutralization of soluble TNF by XPRO™ Boca Raton, Florida, April 19, 2023 (GLOBE NEWSWIRE) - INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused |
|
| April 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2023 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of in |
|
| April 20, 2023 |
Exhibit 10.1 FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT This FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (“First Amendment”) is made as of April 17, 2023 by and between Immune Ventures, LLC (“Licensor”) and INmune Bio, Inc., a Nevada corporation, having a principal place of business at 225 NE Mizner Blvd., STE 640, Boca Raton, FL 33432 (“Licensee”), each a “Party” and collectively the “Part |
|
| April 20, 2023 |
Exhibit 10.2 SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT This SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (this “Second Amendment”) is made as of April 6, 2023, by and between the University of Pittsburgh – Of the Commonwealth System of Higher Education, a non-profit corporation organized and existing under the laws of the Commonwealth of Pennsylvania (“University”) and INmune Bio, Inc (“L |
|
| April 11, 2023 |
Exhibit 99.1 INmune Bio, Inc. to Present Preclinical Data at the 2023 AACR Annual Meeting Showing Improved Outcomes in High-Risk Breast Cancer by Targeting MUC4 Expression with INB03 Two presentations show targeting high-risk MUC4 expressing HER2+ and Triple Negative Breast Cancer with INB03 reverses resistance mechanisms to immunotherapy “Emerging Targeted Therapies for HER2-Positive Breast Cance |
|
| April 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2023 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of in |
|
| April 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2023 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of inc |
|
| April 3, 2023 |
Exhibit 99.1 INmune Bio, Inc. Announces Submission of Investigational New Drug (IND) Application for INKmune™ to the U.S. Food and Drug Administration for Treatment of Metastatic Castration-Resistant Prostate Cancer BOCA RATON, Fla., April 03, 2023 (GLOBE NEWSWIRE) - INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness t |
|
| March 31, 2023 |
INmune Bio Inc. 225 NE Mizner Blvd, Suite 640 Boca Raton, FL 33432 Tel: (858) 964 3720 INmune Bio Inc. 225 NE Mizner Blvd, Suite 640 Boca Raton, FL 33432 Tel: (858) 964 3720 March 31, 2023 Ms. Vanessa Robertson and Mr. Kevin Vaughn Division of Corporation Finance Office of Life Sciences Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: INmune Bio Inc. Form 10-K for the fiscal year ended December 31, 2022 Filed March 2, 2023 File No. 001-38793 Dear Ms. Ro |
|
| March 15, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2023 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of in |
|
| March 15, 2023 |
Exhibit 99.1 I N M B IN V E S T O R PRES E NT A TIO N March 2023 H A R N E SS I N G T H E P O W E R O F T H E I NN A T E I MM U N E S Y S T E M Two Therapeutic Platforms: XPro Œ and INKmune Œ He l p Rep a ir Inn a te Immune D ysfunction F O R W A R D L OO K I N G S T A T E M E N T S This presentation contains “forward - looking statements” Forward - looking statements reflect our current view abou |
|
| March 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of inc |
|
| March 3, 2023 |
INmune Bio, Inc. Announces 2022 Results and Provides Business Update Exhibit 99.1 INmune Bio, Inc. Announces 2022 Results and Provides Business Update Company to Host Conference Call Today, March 2, at 4:30pm ET BOCA RATON, Fla., March 02, 2023 (GLOBE NEWSWIRE) - INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its f |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38793 INMUNE BIO INC. (Exact name of registra |
|
| March 2, 2023 |
EXHIBIT 21.1 Subsidiaries Jurisdiction of Formation INmune Bio International Ltd. England INmune Bio Australia Pty Ltd Australia DN02, Inc. United States |
|
| February 22, 2023 |
Exhibit 99.1 INmune Bio, Inc. to Report Fourth Quarter and Full-Year 2022 Results and Provide a Corporate Update on Thursday, March 2 Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, Feb. 21, 2023 (GLOBE NEWSWIRE) - INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a patien |
|
| February 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2023 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of |
|
| February 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of |
|
| February 15, 2023 |
INMB / INmune Bio Inc. Common stock / Xencor Inc - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 10, 2023 |
Exhibit 99.1 INmune Bio, Inc. Receives Approximately $6.4 Million in Research and Development Rebates from Australia and the United Kingdom BOCA RATON, Fla., Feb. 08, 2023 (GLOBE NEWSWIRE) - INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces that it h |
|
| February 10, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2023 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of |
|
| January 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2023 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of |
|
| January 25, 2023 |
Exhibit 99.1 INmune Bio, Inc. Announces Pre-Clinical Data That Support a Pioneering Approach to Treating Duchenne Muscular Dystrophy Boca Raton, Florida, Jan. 25, 2023 (GLOBE NEWSWIRE) - INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, in collaboration with Profess |
|
| December 22, 2022 |
Exhibit 99.1 INmune Bio, Inc., Virginia Commonwealth University, and Barrow Neurological Institute Receive Department of Defense Funding to Study the Role of Traumatic Brain Injury in the Development of Alzheimer?s Disease XPro1595 decreases development of amyloid beta and tau following TBI in murine model of Alzheimer?s disease Boca Raton, Florida, Dec. 22, 2022 (GLOBE NEWSWIRE) - INmune Bio, Inc |
|
| December 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2022 INMUNE BIO INC. (Exact name of registrant as specified in charter) Nevada 001-38793 47-5205835 (State or other jurisdiction (Commission File Number) (IRS Employer of |
|
| December 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A/A (Amendment No. 2) FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 INMUNE BIO INC. (Exact name of registrant as specified in its charter) Nevada 47-5205835 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identifi |
